%0 Journal Article
%A Eichhorn, Martin E
%A Niedermaier, Benedikt
%A Charoentong, Pornpimol
%A Klotz, Laura V
%A Baum, Philip
%A Griffo, Raffaella
%A Allgäuer, Michael
%A Stenzinger, Albrecht
%A Bischoff, Helge
%A Schneider, Marc A
%A Christopoulos, Petros
%A Haberkorn, Uwe
%A Heußel, Claus-Peter
%A Savai, Rajkumar
%A Roberti, Maria Paula
%A Zoernig, Inka
%A Jäger, Dirk
%A Herth, Felix
%A Thomas, Michael
%A Winter, Hauke
%A Eichhorn, Florian
%T Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial.
%J Journal for ImmunoTherapy of Cancer
%V 13
%N 8
%@ 2051-1426
%C London
%I BioMed Central
%M DKFZ-2025-01627
%P e011874
%D 2025
%X The phase II NEOMUN trial was conducted to investigate the therapeutic effect of preoperative programmed death receptor-1 inhibitor pembrolizumab for treating non-small cell lung cancer (NSCLC). Herein, we report the final efficacy, safety, and long-term survival results.Patients with resectable stage II/IIIA NSCLC were included. Two cycles of pembrolizumab (200 mg intravenously once every 3 weeks) were administered before surgery. The primary objectives were to assess the feasibility and safety of neoadjuvant treatment and evaluate antitumor activity. We analyzed the clinical parameters and pathologic, radiological, and metabolic tumor response data.29 patients with NSCLC were enrolled. NSCLC histology revealed adenocarcinoma and squamous cell carcinoma in 24 and in 5 patients, respectively. 93.1
%K Humans
%K Antibodies, Monoclonal, Humanized: therapeutic use
%K Antibodies, Monoclonal, Humanized: pharmacology
%K Carcinoma, Non-Small-Cell Lung: drug therapy
%K Carcinoma, Non-Small-Cell Lung: pathology
%K Carcinoma, Non-Small-Cell Lung: mortality
%K Male
%K Female
%K Middle Aged
%K Aged
%K Lung Neoplasms: drug therapy
%K Lung Neoplasms: pathology
%K Neoadjuvant Therapy: methods
%K Adult
%K Programmed Cell Death 1 Receptor: antagonists & inhibitors
%K Immunotherapy: methods
%K Immune Checkpoint Inhibitors: therapeutic use
%K Immune Checkpoint Inhibitors: pharmacology
%K Antineoplastic Agents, Immunological: therapeutic use
%K Antineoplastic Agents, Immunological: pharmacology
%K Biomarker (Other)
%K Immune Checkpoint Inhibitor (Other)
%K Major pathologic response - MPR (Other)
%K Neoadjuvant (Other)
%K Non-Small Cell Lung Cancer (Other)
%K pembrolizumab (NLM Chemicals)
%K Antibodies, Monoclonal, Humanized (NLM Chemicals)
%K Programmed Cell Death 1 Receptor (NLM Chemicals)
%K Immune Checkpoint Inhibitors (NLM Chemicals)
%K Antineoplastic Agents, Immunological (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40759442
%R 10.1136/jitc-2025-011874
%U https://inrepo02.dkfz.de/record/303378